Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899600 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL594646 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL594645 | 1.00 | TP53 (0.48) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL28405577 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL6900183 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL234644 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL13011542 | 0.95 | TP53 (0.53) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1169984 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1170182 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 | |
| SCHEMBL1169988 | 0.93 | TP53 (0.52) | TP53CYP3A4ALDH1A1PPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232058-A | Synthesis method of gliclazide intermediate 1,2-cyclopentanedicarboxamide | 上海巽田科技股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2876118-B1 | METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR USE IN POLYMERIZATION OF OLEFIN, CATALYST FOR USE IN POLYMERIZATION OF OLEFIN, AND METHOD FOR PRODUCING OLEFIN POLYMER | TOHO TITANIUM CO LTD (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-2963065-B1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, CATALYST FOR POLYMERIZING OLEFINS, AND PRODUCTION METHOD FOR POLYMERIZED OLEFINS | TOHO TITANIUM CO LTD (JP) | 2018-04-04 | — | — | EP | disclosed |
| EP-2221320-B1 | SOLID TITANIUM CATALYST INGREDIENT, CATALYST FOR OLEFIN POLYMERIZATION, AND METHOD OF POLYMERIZING OLEFIN | MITSUI CHEMICALS INC (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2963063-B1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, CATALYST FOR POLYMERIZING OLEFINS, AND PRODUCTION METHOD FOR POLYMERIZED OLEFINS | TOHO TITANIUM CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9670294-B2 | Method for producing solid catalyst component for use in polymerization of olefin, catalyst for use in polymerization of olefin, and method for producing olefin polymer | TOHO TITANIUM CO., LTD. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9593175-B2 | Solid titanium catalyst component for ethylene polymerization, ethylene polymerization catalyst and ethylene polymerization method | MITSUI CHEMICALS, INC. (JP) | 2017-03-14 | — | — | US | disclosed |
| EP-2221320-A1 | SOLID TITANIUM CATALYST INGREDIENT, CATALYST FOR OLEFIN POLYMERIZATION, AND METHOD OF POLYMERIZING OLEFIN | Mitsui Chemicals, Inc. (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2155687-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20080306228-A1 | Process for Producing Olefin Polymer and Solid Titanium Catalyst Component | MITSUI CHEMICALS, INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080125555-A1 | Catalyst for olefin polymerization and process for olefin polymerization | MITSUI CHEMICALS, INC. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1840138-A1 | PROCESS FOR PRODUCING OLEFIN POLYMER AND SOLID TITANIUM CATALYST COMPONENT | Mitsui Chemicals, Inc. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | TP53 1398/4885CYP3A4 544/4885ALDH1A1 576/4885 |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | TP53 1398/4885CYP3A4 544/4885ALDH1A1 576/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | TP53 4688/4885CYP3A4 1894/4885ALDH1A1 573/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | TP53 2338/4885CYP3A4 2691/4885ALDH1A1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.